Minocycline for Chronic Autoimmune Uveitis

Condition(s) studied

Investigational drug(s) / intervention(s)

minocycline: minocycline capsule 100mg per day orally

Study summary

Autoimmune uveitis is one kind of non-infectious, sight-threatening, relapsing and severe ocular disease. Approximately 20%-25% autoimmune uveitis patients suffer from the dilemma of blindness for the chronic and persistent inflammatory state in the eyes, which results in continuous destroy in the structure of the eyes and gradually leads to irreversible damage on visual function. However, it shows limiting efficacy of current treatment including glucocorticoids, immunosuppressant and biologics for chronic autoimmune uveitis. Minocycline has been regarded to have anti-apoptosis and immunemodulatory function for decades and it has been illustrated to be beneficial in several neuro-degenerative and neuro-inflammatory diseases. This trial aims to investigate the efficacy and safety of minocycline for chronic autoimmune uveitis with retinal degenerative changes.

Eligibility

Primary outcome measure(s)

• Change of macular sensitivity — At 6 and 12 months
  Change of macular sensitivity measured by MAIA
• Change of BCVA — At 6 and 12 months
  Change of BCVA measured by ETDRS
• Change of Visual field — At 6 and 12 months
  Change of Visual field measured by HVF 30-2 visual field testing
• Changes in Implicit Time and Amplitude of Photopic and Scotopic Responses — At 6 and 12 months
  Changes in Implicit Time and Amplitude of Photopic and Scotopic Responses measured by Electroretinogram (ERG) Testing

Trial sites (1)

More Sun Yat-sen University trials in China

Other trials for the same condition